Health · 1 sources covering this

STAT+: FDA reverses course on Regenxbio’s childhood gene therapy after rejection

The FDA will reconsider approving Regenxbio's experimental gene therapy for a deadly and rare childhood brain disorder it rejected just four months ago.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·3h ago
STAT+: FDA reverses course on Regenxbio’s childhood gene therapy after rejection
The FDA will reconsider approving Regenxbio's experimental gene therapy for a deadly and rare childhood brain disorder it rejected just four months ago.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/f9dab910e41a4dcc9f4abd04acfb6e868d82e02e"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: FDA reverses course on Regenxbio’s childhood gene therapy after rejection"></iframe>

STAT+: FDA reverses course on Regenxbio’s childhood gene therapy after rejection

How 1 sources are covering this

STAT+: FDA reverses course on Regenxbio’s childhood gene therapy after rejection

More from Health

STAT+: Another big deal, another sign biotech M&A is back

STAT+: Despite transplant referrals, most kidney patients don’t make the waitlist

STAT+: Pharmalittle: We’re reading about another FDA reversal, pharma’s M&A spree and much more

8 things to know about the gut microbiome and keeping yours healthy

Reader

Trust & legal

Across the network

How 1 sources are covering this

STAT+: FDA reverses course on Regenxbio’s childhood gene therapy after rejection

More from Health

STAT+: Another big deal, another sign biotech M&#038;A is back

STAT+: Despite transplant referrals, most kidney patients don’t make the waitlist

STAT+: Pharmalittle: We&#8217;re reading about another FDA reversal, pharma&#8217;s M&#038;A spree and much more

8 things to know about the gut microbiome and keeping yours healthy

Reader

Trust & legal

Across the network

STAT+: Another big deal, another sign biotech M&A is back

STAT+: Pharmalittle: We’re reading about another FDA reversal, pharma’s M&A spree and much more